SUBSCRIBE
SUBSCRIBE
Tristan Manalac

Tristan Manalac

Contributing Writer | News

Tristan is an independent science writer based in Metro Manila, with more than eight years of experience writing about medicine, biotech and science. Being formally trained in molecular biology, he once dreamed of collecting degrees and starting his own lab. But these days, he finds his greatest joy in a bottle of beer and a beautiful sentence. He can be reached at tristan.manalac@biospace.com, tristan@tristanmanalac.com or on LinkedIn.

Pictured: J&J's building in Switzerland
J&J Cuts R&D at Netherlands Infectious Disease, Vaccine Unit
After slimming down its infectious diseases and vaccines business, Johnson & Johnson now appears to be ending research and development at a Dutch-based unit, except for a few programs.
August 24, 2023
 · 
2 min read
 · 
Tristan Manalac
Pictured: CVS Health's signage outside its office in Texas
Business
CVS Health Enters Biosimilars Market with Launch of Cordavis Subsidiary
The consumer healthcare brand is joining the growing biosimilars market in the U.S. with its new subsidiary Cordavis, which will market a Humira biosimilar as its first product.
August 24, 2023
 · 
2 min read
 · 
Tristan Manalac
Signage outside Genentech's headquarters in Silicon Valley
Drug Development
Roche Reports Positive Phase III NSCLC Data for Anti-TIGIT Candidate After Leak
Spurred by an “inadvertent” disclosure, Roche’s Genentech on Wednesday released interim and immature overall survival findings for its anti-TIGIT antibody tiragolumab in non-small cell lung cancer.
August 23, 2023
 · 
2 min read
 · 
Tristan Manalac
Pictured: Entrance to the U.S. Department of Healt
Policy
Regeneron, J&J Win HHS Funding to Develop Next-Gen COVID Products
Under the $1.4 billion Project NextGen initiative, Regeneron was awarded a $326 million grant for its preventive monoclonal antibody, while Johnson & Johnson got $10 million to bankroll startups.
August 23, 2023
 · 
2 min read
 · 
Tristan Manalac
Pictured: Teva Pharmaceuticals USA headquarters in
Policy
Teva to Pay $225M in DOJ Generic Drug Price-Fixing Settlement
Three years after the initial case, Teva Pharmaceuticals is finally settling its drug price-fixing charges with the Department of Justice for $225 million, payable over a five-year period.
August 22, 2023
 · 
2 min read
 · 
Tristan Manalac
Pictured: Pfizer's signage at its world headquarters in New York
FDA
Pfizer Wins FDA Approval for First Maternal RSV Shot to Protect Infants
The FDA on Monday gave the greenlight to Pfizer’s RSV vaccine for expectant mothers, given during the third trimester of pregnancy, designed to protect newborn babies through the first six months of life.
August 22, 2023
 · 
2 min read
 · 
Tristan Manalac
External view of Boehringer Ingelheim's headquarters in Silicon Valley
Policy
Boehringer Ingelheim Joins Legal Battle Against IRA Drug Pricing Provisions
The German pharmaceutical giant is the latest pharma company to challenge the constitutionality of the Inflation Reduction Act’s drug price negotiation program.
August 22, 2023
 · 
2 min read
 · 
Tristan Manalac
Pictured: Roche Diagnostics building in California
Drug Development
Roche, Exelixis’ Drug Combo Bounces Back with Late-Stage Prostate Cancer Win
After sustaining two Phase III fails, Roche and Exelixis finally reported a late-stage win for their combination regimen of Tecentriq and Cabometyx in metastatic castration-resistant prostate cancer.
August 21, 2023
 · 
2 min read
 · 
Tristan Manalac
FDA signage at its office in Maryland
FDA
Regeneron Expands Eylea’s Label with High-Dose Approval
Following a prior rejection due to manufacturing problems, Regeneron’s higher-dose Eylea won the FDA’s approval Friday, allowing for more infrequent dosing for the treatment of various eye diseases.
August 21, 2023
 · 
2 min read
 · 
Tristan Manalac
Merck Research Laboratories headquarters in Silicon Valley
Drug Development
Merck’s Welireg Clears Phase III Primary Endpoint in Renal Cell Carcinoma
The company is continuing its renal cell carcinoma push for its oral HIF-2α inhibitor Welireg with promising Phase III data showing significant progression-free survival improvements in patients.
August 18, 2023
 · 
2 min read
 · 
Tristan Manalac
Pictured: Man packing up his office things in a bo
Business
Kodiak CMO Steps Down After Phase III Flops for Eye Therapy
After the company’s investigational eye therapy recently failed two late-stage studies, Kodiak Sciences’ Chief Medical Officer and Chief Development Officer Jason Ehrlich has resigned from his roles.
August 18, 2023
 · 
2 min read
 · 
Tristan Manalac
Pictured: Healthcare worker administering a vaccin
Drug Development
Pfizer, Moderna Target Emerging Variants with Updated COVID-19 Shots
The companies contend that their updated COVID-19 vaccines for the fall vaccination season can elicit strong immune responses against the virus’ currently dominant and emerging subvariants.
August 18, 2023
 · 
2 min read
 · 
Tristan Manalac
Pictured: Exterior of an FDA building
FDA
FDA Approves Ipsen’s Palovarotene for Ultra-Rare Bone Disease
After two prior setbacks, the regulator has finally approved Ipsen’s palovarotene to treat fibrodysplasia ossificans progressiva. It’s the first treatment for the ultra-rare bone disease.
August 17, 2023
 · 
2 min read
 · 
Tristan Manalac
Pictured: The U.S. Supreme Court building in Washi
Policy
Federal Appeals Court Rules for Tighter Restrictions on Abortion Pill
Mifepristone’s legal saga continues as the U.S. 5th Circuit Court of Appeals ruled for steep restrictions on the drug’s access, though its effectivity is pending the Supreme Court’s review.
August 17, 2023
 · 
2 min read
 · 
Tristan Manalac
Pictured: FDA signage at its office in Washington, DC
Policy
Bluebird’s Lovo-Cel Gene Therapy for SCD Will Not Face FDA Adcomm
The regulator informed bluebird bio that it will not convene an advisory committee meeting to discuss the company’s application for the gene therapy being developed for sickle cell disease.
August 16, 2023
 · 
2 min read
 · 
Tristan Manalac
Load More